LM-168

N/A

Report date: 2026/04/13 20:02:18

Base Information

Drug NameLM-168
Drug Alias NameLM-168
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionAnti-CTLA4
TargetsCytotoxic T-Lymphocyte-Associated Antigen 4
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryAustraliaMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesLaNova Medicines Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesLaNova Medicines Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumours
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A